170 results
Page 5 of 9
6-K
EX-99.1
302 p9nnrln2o
18 Feb 21
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
8:03am
6-K
EX-99.1
13q0tpeonxj3 ok8u5
16 Feb 21
Current report (foreign)
8:30am
6-K
EX-1.1
x42n5xhfzysk rz
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
6-K
EX-99.1
gibs4e2f2ehp
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
9g6yk8
10 Feb 21
Prospectus supplement for primary offering
5:22pm
FWP
kodzw
10 Feb 21
Free writing prospectus
6:08am
FWP
tc1z27stkrqzi
9 Feb 21
Free writing prospectus
5:21pm
424B5
iid9p4 am9o
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
3z30ug57
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
953j66
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
7gehtnhw0 ss
7 Dec 20
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
ytqp ern3pkcg
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
kwkb7q in
18 Nov 20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
8:02am
6-K
EX-99.1
de1s45 fzcbjb
17 Nov 20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
8:18am
6-K
EX-99.1
eua4ti6ujfee3
12 Nov 20
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
8:01am
6-K
EX-99.1
9kko7tzmnrqo3ex
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.2
8gd pscoery3v
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
72bx9v
27 Oct 20
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
wpwdqi8zvd yziahhx
22 Oct 20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:49am
6-K
EX-10.1
i9e9xfdxera7o8w
22 Oct 20
Report of Foreign Private Issuer
8:47am